Veliparib (ABT-888), which can inhibit cancer growth by blocking DNA base excision repair, is one of several recently developed oral inhibitors of poly(ADP-ribose) polymerases, which are currently used in clinical trials. In this work, interaction of calf thymus DNA (ctDNA) with ABT-888 was first investigated following UV-visible absorption, nuclear magnetic resonance (NMR) spectroscopy, steady-state and time-resolved fluorescence, viscosity measurements, circular dichroism (CD), and Fourier transform infrared (FT-IR) spectroscopy coupled with molecular docking methods. UV-visible absorption indicated that ABT-888 was indeed bound to ctDNA. Broadening and upfield shift of the proton peaks of ABT-888 in the proton NMR spectrum indicated that ABT-888 interacted with ctDNA primarily by partial intercalation.
Introduction
Currently, cancer remains a leading cause of death in countries around the world. A majority of anti-cancer drugs cause cell death through DNA damage, and in this situation, functioning DNA repair pathways act as mechanisms of drug resistance.
1,2
Cancer cells can activate their own DNA damage repair to restore themselves, thus causing drug resistance against anticancer drugs and radiotherapy. 3, 4 Further research indicates that there is over-expression of DNA repair pathways in cancer cells. Thus, blocking DNA damage repair pathways is an important and new method of cancer therapy. Polyadenylation diphosphate ribose transferase (poly ADP-ribose polymerase, PARP) is a DNA repair enzyme, which plays a key role in DNA repair pathways. The superfamily of PARPs consists of six different enzymes: PARP-1, PARP-2, PARP-3, PARP-4/VPARP, tankyrase-1 and tankyrase-2.
5
These enzymes engage in various cellular functions, including cell cycle regulation, transcription, and DNA damage repair. 6 Thus, PARP inhibitors could be developed as chemosensitizers of DNA-damaging agents. PARP-1 is currently the best characterized enzyme in this group and is critical to repair of breaks in single-strand DNA through base excision repair pathway.
5,7
Veliparib (also called ABT-888) is a novel oral benzimidazole derivative and is the most represented PARP-1 inhibitors.
8 Fig. 1 shows the complete chemical name of the compound (2-[(R)-2-ethylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide) and its chemical structure. In vivo and in vitro experiments conrmed that ABT-888 increases cellular apoptosis and consequently inhibits cancer growth via blocking DNA base excision repair. [9] [10] [11] Efficacy and safety data from recent phase I and II trials demonstrated that ABT-888, in combination of cytotoxic agents or as monotherapy, was well-tolerated and showed anticancer activity. 12, 13 In treatment of metastatic breast cancer, colon cancer, metastatic melanoma, and brain tumor, the compound has signicant effects, and its combination with temozolomide is going to enter phase III clinical trials for treatment of breast cancer.
14 Recent studies reported that ABT-888 also inhibits vessel formation in radiated cells. 13 Many reports focus on functional targets of ABT-888, but none centered on detailed aspects of binding mode and binding region of ABT-888 and DNA and DNA structural change. Interestingly, investigation of interactive nature of ABT-888 with DNA can provide insight into drug anticancer activities involved in DNA damage repair pathways and provide support for continued clinical investigation of the drug.
Given the information above, this work aimed to investigate the mechanism of interaction (including binding mode, binding region, and structural feature) between ABT-888 and DNA using calf thymus DNA (ctDNA) in vitro under simulated physiological conditions. ctDNA has a relatively low protein content with a highly polymerized DNA skeleton which contains alternating sugar phosphate sequence. 15, 16 It is a natural DNA widely used in studies of binding between DNA and anticancer agents, which modulate DNA structure and function. [17] [18] [19] It is also used in physicochemical studies of DNA behavior in solution. In the present study, UV-visible absorption and proton nuclear magnetic resonance ( 1 H NMR) investigations were carried out to explore whether ABT-888 binds to ctDNA in solution. The quenching mechanism, binding constants, number of binding sites, and thermodynamic parameters were evaluated by steady-state and time-resolved uorescence spectroscopy. Ethidium bromide (EB) and Hoechst 33258 were used as DNA probes for comparative study of the interaction of ABT-888 with ctDNA helix, and comparison was further supported by viscosity measurements, circular dichroism (CD), and Fourier transform infrared (FT-IR) spectroscopy. Furthermore, molecular docking was used to interpret experimental observations and to propose a three-dimensional (3D) model for the binding region of ctDNA-ABT-888 complex.
Materials and methods

Materials
Veliparib (purity > 99%) was purchased from Selleck (USA) 
where [ctDNA]) concentration ratios, where h is viscosity contributions of ctDNA in the presence of ABT-888, and h 0 is viscosity of ctDNA alone. 2.3.7. CD spectroscopy. Far UV-CD measurements (230-320 nm) were conducted on a Hitachi-F7000 uorescence spectrometer, which used a quartz cell with path length of 0.1 cm at 298 K, equipped with R3788 photomultiplier. Concentration of ctDNA was kept at 3.5 Â 10 À4 M while ABT-888 concentration varied from 0 to 8.0 Â 10 À5 M. All observed CD spectra were corrected for buffer signal, and results were expressed as ellipticity. Each CD spectrum was scanned at 60 nm min
À1
, and data points were recorded at 1 nm intervals for three-scan accumulations.
2.3.8. FT-IR spectra. IR spectra within 1850-900 cm À1 with resolutions of 4 cm À1 and 128 scans were recorded on a Nicolet-6700 FT-IR (Thermo, US) spectrometer with a smart OMNIsampler accessory. Background atmospheric spectrum was collected before each measurement. Corresponding absorbance contributions of the buffer and free ABT-888 solutions were recorded and digitally subtracted from the spectra of free ctDNA and ABT-888-ctDNA complex solutions. 18 All spectra data were analyzed using rst derivative combined with Savitzky-Golay lter smoothing. 2.3.9. Molecular docking analysis. MGL tools 1.5.4 with AutoGrid4 and AutoDock4 (ref. 24 and 25) were used to set up and perform blind docking calculations between the drug and DNA sequence. The 3D structure of ABT-888 was constructed from a 2D structure and geometry was optimized using the Discover Minimization tool in Materials Studio 6.0 soware (Accelrys Co. Ltd, California, USA). Crystallographic structure of DNA duplex was obtained from the Protein Data Bank, using identier 1BNA [(CGCGAATTCGCG)2] (http://www.rcsb.org/ pdb). Before docking analysis, DNA structure was modied to remove water molecules and to add polar hydrogen atoms and Gasteiger charges. DNA was enclosed in a box with number of grid points in x-, y-, and z-axes, 60 Â 68 Â 126Å 3 , and grid spacing of 0.375Å. Grid center was set to positions of 14.780, 20.976, and 8.807. Parameters were used throughout docking. Aer grid map generation, 200 Lamarckian genetic algorithm runs were carried out using 250 000 energy evaluations and 27 000 generations. All other parameters were measured at default setting. The lowest energy docked conformation, according to AutoDock scoring function, was selected as binding mode.
Results and discussion
UV-visible absorption studies
The strength and nature of binding interaction between ABT-888 and ctDNA can be obtained from the absorption titration method by following the changes in the absorbance and shi in the wavelength of DNA-drug complex. [26] [27] [28] Most of small molecules noncovalently interact with DNA through three distinct mode types: (I) intercalation, (II) partially intercalated binding, and (III) groove binding, which can be stabilized by hydrophobic, electrostatic, and hydrogen bonding interactions.
18,29,30
The absorption spectra of ABT-888 in the absence and presence of increasing concentration of ctDNA were recorded and are shown in Fig. 1 . The inset shows the characteristic maximum absorption of ctDNA and ABT-888 centered at 271 and 296 nm in the wavelength range of 230-350 nm, respectively. With the gradual addition of ctDNA (0-22.8 Â 10 À5 M) to the xed concentration of ABT-888 (8.0 Â 10 À5 M), there was a continuous increase of the absorption spectrum of ABT-888. Fig. 1 clearly shows the occurrence of the hyperchromicity of absorbance at 271 nm along with a blue shi of about 9 nm. In addition, the absorption peak at 296 nm gradually disappeared with the increasing concentration of ctDNA. These changes may be a result of the interaction of ABT-888 with ctDNA. Some investigators have reported that the binding of small molecules to the base pairs of DNA through intercalation usually results in hypochromic (or hyperchromic) effect and a red shi of the small molecules absorption band. 20 Thus, our results show that ABT-888 is likely to interact with ctDNA through mixed-ligand type binding modes. Since the UV-visible spectroscopic results did not provide some dened evidence regarding the nature of binding between ABT-888 and ctDNA, some other experiments were needed to conrm the strength and nature of this interaction and its clear-cut binding mechanism. Fig. 2A and B clearly shows line broadening of H-a, b, c, and d proton peaks aer adding ctDNA, indicating that addition of ctDNA inuences the microenvironment around ABT-888 protons.
35 Table 1 shows the upeld shi of proton resonances of a, b, c, and d hydrogen atoms in the presence of ctDNA, indicating that p-p stacking interactions between ABT-888 and base pairs of ctDNA possibly exist, and magnetic shielding effects resulted in increased electron density in the surroundings of these protons aer binding. Zhang et al. 32 suggested that magnetic shielding effects may be caused by hydrogen bond formation between small drug molecules and ctDNA. There was a phenomenon that changes in the chemical shis of the hydrogen of the benzimidazolyl moiety of ABT-888 were greater than those of the hydrogen of pyrrolidyl moiety in the presence of ctDNA (Table 1) . This difference implies an unequal participation of the two moieties of ABT-888 in the formation of the complex and the benzimidazolyl moiety may be more intimate contact with ctDNA. Broadening and upeld shi of peaks of ABT-888 in the presence of ctDNA indicate that ABT-888 indeed bound to ctDNA through partial intercalation binding.
Analysis of uorescence quenching
Fluorescence titration experiment was used to study relative binding of ABT-888 to ctDNA. Fluorescence signal was not observed for the sample with ctDNA alone in the buffer solution. However, ABT-888 exhibited strong uorescence emission peak at 360 nm with excitation wavelength at 271 nm. In the present study, ABT-888 and ctDNA interaction was investigated by gradually adding ctDNA to ABT-888 solution (5.0 mM). Fig. 3A shows the remarkable decreasing trend of emission intensity of ABT-888 at 360 nm with increasing concentrations of ctDNA. Quenching rate was 53.5%, and there was a slight blue shi (2 nm) at the maximum wavelength of ABT-888 uorescence emission when the solution of ctDNA was added. Sameena and Enoch 27 suggested that such a blue li showed the increase in the hydrophobicity around the macromolecule due to the formation of new non-uorescent complex between small molecule and macromolecule. Therefore, the results indicated that ctDNA could quench the intrinsic uorescence of ABT-888, and that binding of this compound to ctDNA indeed exists. Results further support the ndings of UV absorption and 1 H NMR.
Different quenching mechanisms are usually classied as dynamic or static quenching, and the two can be distinguished by analyzing uorescence data at different temperatures. Decrease in uorescence intensity is described by the SternVolmer equation:
where F 0 and F denote uorescence intensities in the absence and presence of quencher, respectively; [Q] is the quencher concentration; K SV is the Stern-Volmer quenching constant, which is determined by linear regression of a plot of quenching were differentiated. Dynamic quenching depends upon diffusion. Since the higher temperature leads to the larger diffusion coefficients, the K SV increases with rising the temperature. In contrast, increased temperature is likely to cause the decrease of complex stability, and thus lower values of the static quenching constants were resulted. 20 Fig . 3B and Table 2 present the decreasing trend of K SV values with increasing temperature. Therefore, uorescence quenching mechanism of ABT-888 by ctDNA may be controlled by static rather than dynamic quenching along with ctDNA-ABT-888 complex formation.
To further substantiate the quenching mechanism, uores-cence lifetime measurements were carried out on a singlephoton counting setup given that lifetime would be unaffected in ground-state quenching but would decrease in the excited-state type.
38 Time-resolved uorescence decay of ABT-888 was ascertained in the absence and presence of various concentrations of ctDNA (Fig. 4) . All time-resolved uorescence data were analyzed by bi-exponential iterative ttings. Fitting parameters are listed in Table 3 . Goodness of t was evaluated from reduced chi-square (c 2 ) values, and in general, c 2 < 1.3 is acceptable. Mean uorescence lifetimes (s avg ) were calculated from the decay times (s 1 , s 2 ) and normalized pre-exponential factors (a 1 , a 2 ) using the following equation: 
Table 2 Association constants and thermodynamic parameters at different temperatures for the ctDNA-ABT-888 interaction
As mentioned in Table 3 
Determination of binding constants and number of binding sites
From variations in intrinsic uorescence of small molecules in the presence of ctDNA, binding constant (K b ) between small molecules and ctDNA can be possibly calculated. 19, 20 Thus, binding constant (K b ) and a number of binding sites (n) in ABT-888 and ctDNA were determined from the above uorimetric titration. Parameters were calculated using the following equation:
where F 0 and F denote uorescence emission intensity of ABT-888 in the absence and presence of ctDNA; [Q] is ctDNA concentration. Fig. 3C presents the plots of log(F 0 À F)/F versus log[Q], and 42 but higher than N,N-bis(3b-acetoxy-5a-cholest-6-yl-idene) hydrazine (4.7 Â 10 3 M À1 ), which binds to DNA in groove-binding mode. 43 Thus, results indicate that DNAbinding mode of ABT-888 is not simple intercalation or groovebinding; such observation is consistent with UV-absorption and 1 H NMR results.
Determination of thermodynamic parameters
Thermodynamic analysis is normally used to determine the essence of interaction between small molecules and biomolecules. Interaction forces between small molecules and biomolecules may involve van der Waals interactions, hydrophobic forces, hydrogen bonds, electrostatic interactions, etc. 25, 40 To characterize the binding force involved in ABT-888 and ctDNA, thermodynamic parameters, such as enthalpy change (DH), entropy change (DS), and free energy change (DG) of the interaction, were determined using the following equations:
where R is the gas constant, and temperatures are same as those in quenching mechanism studies. DH and DS values were obtained from slope and intercept of the linear plot (eqn (5)) based on ln K b versus 1/T, and DG values were estimated from eqn (6) at corresponding temperatures (Fig. 3D) . DH was À14.00 kcal mol À1 , and DS was À24.80 cal mol À1 K À1 ( Table 2 ), indicating that hydrogen bond and van der Waals play major roles in ABT-888-to-ctDNA binding. Per the rules summarized by Ross and Subramanian, 44 negative values of DH and DG revealed that the interaction was spontaneous and predominantly enthalpicallydriven reaction.
Competitive displacement assay
To corroborate the interacting mode, competition binding experiments were carried out using two well-known DNA binding dyes, EB and Hoechst 33258. Dye-competition-binding study can conrm whether this dye and an unknown drug compete for the same binding locus on the DNA. EB is a classic intercalating dye that can produce bright, intense uorescence when it binds to DNA. 45, 46 Changes observed in the uorescence intensities of the ctDNA-EB complex are associated with quenching of its luminescence. Such events may indicate displacement of intercalating EB and efficient interaction of the studied compound with the DNA helix. Hoechst 33258 binds strongly to the minor groove of double-stranded B-DNA with specicity for A-T rich sequence. 47 Addition of excess unknown drug in solution containing Hoechst 33258 and DNA reduces uorescence intensity of Hoechst 33258-DNA complex when the drug also binds to the groove region.
In this study, EB was rst selected as uorescence probe to explore the binding mode between ABT-888 and ctDNA, and molar ratio ([ctDNA]/[EB]) of 14.5 was used as basis for EB uorescence intensity, which did not further increase upon sequential addition of DNA to EB solution. Fig. 5A displays the effect of increasing concentration of ABT-888 on uorescence spectra of EB-ctDNA complex. Apparently, uorescence intensity of EB-ctDNA complex at 601 nm remarkably decreased with increasing concentrations of ABT-888 until measurements reached 1.8 Â 10 À4 M. Such result suggests that ABT-888 could interact with DNA through a similar intercalative mode and was able to replace the intercalation-bound EB dye from doublestranded DNA. Under the same molar ratio of dye-ctDNA (14.5), Hoechst 33258 competition displacement assay was also conducted. Upon subsequent addition of ABT-888, maximum emission wavelength (464 nm) signicantly decreased in the Hoechst-ctDNA system (Fig. 5B) , suggesting that some Hoechst 33258 molecules were released from Hoechst 33258-ctDNA aer an exchange with ABT-888. Results indicate that groove binding is also an interaction mode between ABT-888 and ctDNA. Thus, ABT-888 is not a simple intercalator or groove binder. Instead, ABT-888 and ctDNA bind with each other through a mixed type or partial intercalated mode of DNA binding.
Viscosity measurements
Viscosity measurement is a hydrodynamic method of determining the binding mode of drugs with DNA. 48 A classical intercalation binding requires separation of adjacent base pairs to accommodate binding drug molecules into the double helix of DNA, leading to an increased contour length of DNA and DNA viscosity.
32 By contrast, a drug molecule that interacts with DNA by groove binding or electrostatic interaction does not change the relative viscosity of DNA, because molecules do not alter the axial length of DNA upon binding. 31, 32 In addition, a partial or non-classical intercalation of drug molecules could bend or kink DNA helix, resulting in decreased effective length of DNA molecule with concomitant decrease in its viscosity. At lower r i values, relative viscosity showed a decreasing trend, which then increased at higher mole ratios up to the initial viscosity. We then conclude that at low amounts of ABT-888, drugs bind to ctDNA by partial intercalation mode, whereas at higher drug concentrations, intercalation of ABT-888 into the adjacent base pairs of ctDNA increases the effective length of DNA.
CD study
CD titration is one of the most direct means of examining the binding modes of drug molecules to DNA. Within visible range, a majority of drug molecules do not show any ellipticity in CD spectra. However, right-hand B form of DNA produced a characteristic spectrum with a positive band at 275 nm because of base-stacking and a negative band at 245 nm because of polynucleotide helicity.
49 Simple groove-binding and electrostatic interaction of drug molecules with DNA show little or no perturbations on base stacking and helicity bands, whereas intercalation changes the intensities of both bands, stabilizing the right-handed B conformation of DNA. 50 As shown in Fig. 5D , upon addition of ABT-888 to ctDNA, characteristic CD spectrum of ctDNA undergoes changes in both bands. Moreover, ABT-888 increase moderately intensities of the positive band at 275 nm and decrease moderately that of the negative band at 245 nm. However, interestingly, ABT-888 did not affect the peak shapes of ctDNA. Observation of increased CD signals at 275 nm is an important evidence of interaction of ABT-888 with the base pairs, resulting in the conformational changes in ctDNA.
50
Possibly, different changes in both bands resulted from binding of ABT-888 with ctDNA via mixed binding or partial intercalation mode; such result is consistent with conclusions of above competition experiments.
FT-IR studies
FT-IR spectroscopy has emerged as an efficient tool for characterization of drug-biomolecules interaction and for identi-cation of biomolecule conformations. 17 Earlier experiments demonstrated that infrared spectra of DNA consist primarily of three principal regions. 51 The rst region ($1750-1600 cm À1 )
contains absorption bands assigned to ring stretching vibrations of nitrogenous bases (C]O, C]N, C]C) and bending vibrations of exocyclic NH 2 in the DNA duplex. 52 The second region ($1600-1500 cm
À1
) results primarily from purine and pyrimidine ring vibrations. The last region ($950-1250 cm À1 ) is mostly due to stretching vibrations of symmetric and asymmetric PO 2 groups in the phosphodiester-deoxyribose backbone. 53 Specically, vibrational bands of free DNA at 1710, 1663, 1608, and 1491 cm À1 were assigned to guanine, thymine, adenine, and cytosine nitrogenous base, respectively.
17,33
In this study, diverse IR spectra were obtained by addition of different amounts of ABT-888 to ctDNA solution, as evident in ) also showed obvious shis, which correspond respectively to NH 2 scissoring and N-H bending changes in purine and pyrimidine ring. 29 Major shis in IR bands specify ABT-888 intercalation between A/T and G/C base pairs. The band at 983 cm À1 also shied to 1006 and 1013 cm À1 , and a new absorption band appeared at 950 cm À1 , indicating that phosphate backbone was weak inuenced by ABT-888 interaction with ctDNA. In view of free ctDNA and its complexes spectra, these changes are clearer in the rst derivative spectrum ( Fig. 6D and E) . These feature changes imply that ABT-888 induces local conformational changes in ctDNA to accommodate molecules between base pairs. Result was consistent with that suggested by above CD spectra.
Molecular docking analysis
Molecular docking is an accepted method in search of therapeutic agents designed to interact with a specic biomolecule. Especially in studies of binding of small molecules to DNA, docking underwent substantial development in the last few years. The method allows for virtual screening on large libraries of compounds, ranking of results, and proposing structural hypotheses on how small molecules bind to DNA.
19,20,54
Molecular docking calculations were performed using AutoDock strategy to search the entire DNA surface for binding locus while simultaneously optimizing conformation of base pairs. Geometry-optimized ABT-888 molecule was successfully docked onto DNA segments. A total of 11 multimember conformational clusters were gathered from 200 docking runs, in which case the highest populated cluster contained almost half of the obtained conformationals and was lowest on energy scale. covalent interaction, that is, van der Waals and electrostatic interactions exist between ABT-888 and DNA. Interactions may be either through phosphate backbone atoms of DNA or via the DNA bases.
Optimum binding conformation between ABT-888 and DNA with the lowest binding energy of À9.38 kcal mol À1 was selected for discussion and shown in Fig. 7 . As shown in Fig. 7 , it was obvious that the benzimidazolyl moiety of ABT-888 bound into the base pairs of DNA by parallel way, while the pyrrolidyl moiety was perpendicular to the base pairs. And the hydrogen atoms (a, b, c) of the benzimidazolyl moiety located inside, which shows that the benzimidazolyl moiety is closer to the inside of DNA duplex. The result was coincided with the deduction of 1 H NMR study. Fig. 7 also shows that ABT-888 binds mainly to minor grooves in A-T base pairs region of DNA. ABT-888 bends base pairs by intermolecular hydrogen bonds, namely, the ABT-888 three N-H groups, which forms three hydrogen bonds with DT7, DA17 and DT20, respectively. The O-2 oxygen of DT7 is at a distance of 2.13Å from the NH 2 amide H atom of ABT-888. Similarly, O-3 oxygen of DT17 is 1.95Å from the NH imidazole H atom of ABT-888, and O-3 oxygen of DT20 with the NH pyrrole H atom is 1.96Å. Based on above analysis, groove binding interaction may be play a major role in binding of ABT-888 to DNA, whereas other binding types, including classic intercalation and partial intercalation, cannot be ruled out. Thus, molecular docking studies shed light on binding modes between ABT-888 and DNA and complement experimental observations.
Conclusions
The present study attempted to analyze binding properties of ABT-888 to ctDNA. From these multispectroscopic experiments and molecular docking studies, results showed that mixedligand type binding occurs between ABT-888 and DNA with a binding constant of 9.17 Â 10 4 M À1 at 295 K. Calculated thermodynamic parameters suggested that binding of ABT-888 to ctDNA is driven mainly by hydrogen bonds and van der Waals force. Competition uorescence displacement experiments were studied using EB and Hoechst 33258 as probes for intercalation and minor groove binding modes, respectively, and these experiments indicated that ABT-888 can compete simultaneously for binding sites on ctDNA with the two probes. In viscometric titration, relative viscosity of ctDNA decreased and increased steadily at low and high ABT-888 concentration regions respectively, suggesting transition from predominantly partial intercalation to predominantly classic intercalation. Changes in CD and FT-IR spectra indicated that ABT-888 induces conformational transformation of ctDNA. Theoretical calculations applying AutoDock have been carried out, and calculational results can reasonably complement experimental ndings when ABT-888 interacted with DNA by groove binding mode. 
